Toronto, Canada — May 17, 2025 — Panaxium is honoured to have been selected as one of Canada’s Top 20 Moonshot Ventures™ of 2025, following a closed-door showcase at the National Angel […]
Precision Directed
We imagine a future where permanent disability from brain injury no longer exists.
Modern neuroscience has discovered how the human brain can be intentionally rewired post-injury – but the tools do not exist yet.
1 in 3 people
will survive a stroke or traumatic brain injury in their lifetime – but still be left with life-altering disability.
Our Solution
Get In and Get Out.
We believe the purpose of the ultimate brain-machine interface is
to heal the human brain.
Panaxium’s precision therapy BMI platform is built for surgeons and neurologists to directly intervene, treat the injury, and leave the patient to return to a life of normalcy.
Panaxium’s precision therapy BMI platform is built for surgeons and neurologists to directly intervene, treat the injury, and leave the patient to return to a life of normalcy.
An up close approach
Iontronic interface safely & selectively “speaks” the language of cells to direct precision healing.
It’s not just about the hardware: Precision healing requires advanced understanding of an injury
Panaxium’s proprietary MRI protocol & AI-assisted analysis
generates complete patient-specific representations of entire
functional networks.
This identifies specific disruption from damage, predicts natural
recovery, and aids planning for the implantation.
Together these technologies will enable the ultimate therapy: turning everyday activities into assisted recovery exercises.
In the OR, faster
Partnership with Synaptive Medical
Unlocking the ultimate brain-machine interface neuro-recovery therapy is not just about the device itself. It requires the ability to assess, plan, and strategize a personalized functional remapping to every patient’s specific injury.
Recent News
Panaxium Invited to Join International Research Exchange IONBIKE 2.0
Short-term research and innovation collaborations across industry and academia aim to push the boundaries of eutectogels and fully explore science and technology applications in energy, bioelectronics, and the environment sectors. […]
Ontario Brain Institute Invests in Panaxium to Fund Preclinical Work for Novel Neuromodulation Stroke Therapy
Equity investment from leading brain-focused foundation will fund preclinical work required to begin human clinical trials. Toronto, Canada, April 10, 2023 – Bioelectronic medicine company Panaxium today announced that it has received an […]
Panaxium Presents Brain Machine Interface Precision Neurostimulation Therapy at 2023 Ontario Bioscience Innovation Organization (OBIO) Investment Summit
Panaxium COO Jonathan Balfour presents novel brain machine interface device platform at OBIO Investment Summit 2023 in Toronto, Canada.
Professor Numa Dancause Joins Panaxium Therapy Development Team as Scientific Advisor and Pre-Clinical Collaborator
World-leader in cortical motor control research and Université de Montréal Professor is an expert in premotor cortex function and cortical plasticity following brain injury.
Dr. Gilles Huberfeld to Lead First In-Human Trial of Panaxium’s Next-Generation Brain Computer Interface
Dr. Gilles Huberfeld, MD, PhD, is leading the 1st humans patient investigations of Panaxium's next-generation iontronic brain computer interface in 2023 in Paris, France.
Panaxium Wins 1st Place Jury Prize at 2022 Brain Innovation Days
Panaxium won the 2022 Brain Innovation Days 1st Place Jury Prize at the conference’s pitch competition held in Brussels, Belgium, on October 12, 2022.
Panaxium to Present Novel Neural Interface Data at Asilomar Bioelectronic Symposium 2022
Interactive symposium with leading experts and rising stars in the field will focus on defining the frontiers of bioelectronics and mapping future directions.